파로스백신

본문 바로가기
사이트 내 전체검색

파로스백신

history

  • 2020
    03

    relocated to new office – Seongnam SK V1tower, GMP facility under construction

    06

    AMI-DC IND approved by MFDS, Korea

  • 2019
    01

    secured investments worthy of about 21 billion KRW via CB issuances at home and overseas

    05

    signed international ‘aCD19 CAR T-cell’ joint R&D agreement with BIOCURE PHARM Inc.

    12

    secured NDA of animal medicine ‘PharoVax®-FMD’ – Animal and Plant Quarantine Agency

  • 2018
    07

    signed property contract for new office, research institute, and GMP – Seongnam SK V1tower acquired NET Certificate – Manufacturing Technology of Bivalent Vaccine Composition for Foot-and-Mouth Disease (Ministry of Agriculture, Food and Rural Affairs) signed consignment contract of manufacturing and test of FMD vaccine with CTCBIO Inc.

    08

    filed for NDA of FMD bivalent vaccine and certified as business of consigned manufacturing and sale by Animal and Plant Quarantine Agency

  • 2017
    03

    IND of FMD vaccine (PharoVax®-FMD) by Animal and Plant Quarantine Agency

    08

    signed government-granted project - Study on Optimization of Immunosuppressive Factor-Resistance CAR T-cell Therapy

    09

    [FMD patent registration] EU-UK, Germany, France, Turkey

    11

    signed domestic ‘aCD19 CAR T-cell’ technology transfer and joint R&D agreement with BIOCURE PHARM Inc.

  • 2016
    01

    complete construction of LABII – only for the development of cell therapies

    03

    signed government-granted project – Development of Adjuvant Fit for Recombinant Protein Antigen for FMD Vaccine (Ministry of Science, ICT and Future Planning)

  • 2015
    01

    [FMD patent registration] Canada

    08

    acquired NET Certificate – Manufacturing Technology of FMD Vaccine Composition (Ministry of Commerce, Industry and Energy) signed ‘aCD19+D CAR T’ R&D agreement (China)

  • 2014
    01

    signed joint R&D agreement - A Study on the Industrialization of Safe Foot-and-mouth Vaccine Using Expressed-Bacillus Recombinant Protein

    02

    certified as Venture Business (R&D-Centered Business) – Korea Technology Finance Corporation

    04

    [FMD patent registration] China

    06

    [FMD patent registration] Japan

    11

    [FMD patent registration] Hong Kong

    12

    signed joint R&D agreement with Catholic University of Korea’s industrial-academic cooperation group – Convergence Research Project on Leading Immune diseases (tDC post AMI)

  • 2013
    03

    initiated FMD-O type animal test with cows (Korea)

    09

    [FMD patent registration] Australia/Korea

    10

    [FMD patent registration] USA

  • 2012
    10

    initiated the export of ‘AEC-RIL2’ recombinant protein reagent to China

    12

    signed joint R&D agreement with CHA university – T-cell cultivation technology

  • 2011
    04

    founded (April 8th 2011)

    08

    manufactured FMD-O type test vaccine and initiated animal test with pigs (Korea, China)

회원로그인

접속자집계

오늘
249
어제
2,082
최대
3,999
전체
463,186

그누보드5
Copyright © 소유하신 도메인. All rights reserved.